Secondary Databased Post-marketing Surveillance Study of BNT162b2

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

May 28, 2025

Study Completion Date

May 28, 2025

Conditions
COVID-19SARS-CoV-2
Interventions
BIOLOGICAL

Tozinameran (BNT162b2)

"1. 12 years or older~ * Primary series: 2 doses, 30 μg each, administered 21 days apart~ * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~ * Primary series: 2 doses, 10 μg each, administered 21 days apart~ * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~ * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)"

BIOLOGICAL

Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)

"1\. 12 years or older~\- Single booster dose, 15/15 μg, administered after ≥3 months after primary series"

BIOLOGICAL

Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

"1\. 12 years or older~\- Single booster dose, 15/15 μg administered after ≥3 months after primary series"

Trial Locations (1)

Unknown

Pfizer, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY